Stopping Lymphedema Starts with PREVENT - Final 3-Year Primary Endpoint Results Published


Discover advanced educational opportunities. Register for an upcoming event or access our past events.

Why Expanding Access to a Lymphedema Prevention Program is Needed for Cancer Patients


Lymphedema Prevention Program

Enhance Survivorship and Maximize Patient Health

Understanding fluid shifts that occur in the body can help in the early detection, management, and monitoring of chronic diseases. Lymphedema, most frequently caused by cancer or cancer treatments such as surgery, radiation, and chemotherapy, is one of the most feared consequences of cancer treatment among survivors. If left untreated it can become a lifelong condition.

Proactive Care

Obtaining a baseline L-Dex® score and body composition measurements upon cancer diagnosis is important to detecting lymphedema and enhancing cancer survivorship.

Precision Data

Utilizing the SOZO® Digital Health Platform in your clinical practice can greatly improve the quality of life for cancer patients and survivors.1

Impedimed product

Dr. Pat Whitworth and Dr. Laura Lawson from the Nashville Breast Center explain why lymphedema prevention is a key component of a cancer survivorship program, and share their experience how implementing a lymphedema protocol, utilizing SOZO with L-Dex, has greatly improved the treatment and outlook for their patients.

SOZO Device with L-Dex

SOZO Digital Health Platform

Take advantage of SOZO’s powerful data to detect and manage chronic disease:

  • Early Detection – Detect changes and intervene early in the course of a disease
  • Treatment Monitoring – Monitor the impact of therapeutic interventions
  • Patient Education – Motivate patients to comply with treatment
Learn More About SOZO

Oncology Solutions

L‑Dex Analysis & Lymphedema Prevention Program

Offer your patients peace of mind.

  • Limb lymphedema impacts 1 in 3 at-risk cancer patients2, 3
  • In the largest randomized trial to assess lymphedema prevention in breast cancer patients, 92% of patients with early detection using L-Dex and intervention did not progress to chronic lymphedema1
  • Learn more about ImpediMed’s Lymphedema Prevention Program for early detection and intervention of cancer-related lymphedema utilizing L‑Dex and the Test, Trigger, Treat® protocol.

The L-Dex score, only available from ImpediMed, is designed to detect lymphedema-related fluid changes in the limbs.

Learn more about L‑Dex

The Lymphedema Prevention Program (LPP) is a comprehensive program for early detection and intervention of cancer-related lymphedema.

Learn more about LPP

ImpediMed SOZO Body Composition Analysis Actionable Results

BodyComp Analysis

Empower your patients to change habits and take charge of their health.

  • “Normal” BMI is not necessarily better: overweight and moderately obese cancer patients (BMI 25-35 kg/m2) often have a lower risk of overall mortality4
  • Low muscle mass is associated with higher risk of cancer recurrence, greater overall and cancer-specific mortality, higher rate of surgical complications, and more treatment-related toxicities4
  • Tracking changes in body composition provides insight into disease progression or treatment success and motivates patient compliance

BodyComp Analysis provides a complete fluid, tissue, and metabolic analysis of the human body.

Learn more about BodyComp Analysis

BodyComp Analysis Screen

Segmental BodyComp Analysis

Inspire your patients to care for their whole self.

  • Limb volume does not equal limb composition. Two limbs with the same volume can have different composition – fluid, muscle, and fat.
  • A study5 of breast cancer survivors showed differences in lean mass and fat mass between affected and unaffected arms without differences in volume
  • A true measure of limb composition is needed to guide treatment decisions and evaluate impact of therapy

Segmental BodyComp Analysis provides a detailed analysis of each arm and each leg.

Learn more about Segmental BodyComp Analysis

ImpediMed SOZO Segmental Analysis Detailed Analysis


Final 3-Year Primary Endpoint Results Published

Clinical Evidence

Lymphedema Prevention

A randomized trial, meta-analysis, and six independent studies consistently demonstrate that early detection with L-Dex and intervention reduces progression to chronic cancer-related lymphedema.

L-Dex Validation

L-Dex is validated to detect lymphedema at its earliest, subclinical stage. It can detect fluid shifts as small as 36 mL (2.4 tbsp)6

L-Dex Economics

Early detection and intervention of cancer-related lymphedema is shown to reduce the cost of care compared to treating advanced lymphedema.

Clinical Practice Guidelines

NCCN Guidelines® recommend patient education and regular monitoring for the early detection of lymphedema.

Learn More

Additional guidelines support early detection and intervention


Oncology Resources

ImpediMed Webinars and Events

Webinars & Events

ImpediMed Academy training events and webinars are held throughout the year. See what is coming up as well as view past events.

ImpediMed Academy


Check out the latest news about ImpediMed products, technologies, clinical trials, partnerships, and financials.

ImpediMed Reimbursement Guides


Learn more about reimbursement for L-Dex® analysis for lymphedema and ImpediMed’s Case Assistance Program


  1. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology 2022.
  2. NIH, National Cancer Institute: accessed April 30, 2019.
  3. Shaitelman SF, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin 2015;65:55-81.
  4. Caan, BJ et al. The Importance of Body Composition in Explaining the Overweight Paradox in Cancer. Cancer Res. 2018 April 15; 78(8): 1906 – 1912. doi:10.1158/0008-5472.CAN-17- 3287
  5. Artese AL et al. Assessment of Arm Lean Mass, Fat Mass, and Bone MineralDensity in Breast Cancer Survivors Without Lymphedema. Oncol Nurs Forum. 2021 Mar 1;48(2):166-172. doi: 10.1188/21.ONF.166-172. Affected arm = side with breast cancer; Unaffected arm = side without breast cancer
  6. Ward, L. Is BIS ready for prime time as the gold standard measure. Jrn Lymphoedema 2009;4(2)